Dual-targeting therapeutics by coadministration of allosteric and orthosteric drugs is drawing increased attention as a revolutionary strategy for overcoming the drug-resistance problems. It was further observed that the occupation of orthosteric sites by therapeutics agents has the potential to enhance allosteric ligand binding, which leads to improved potency of allosteric drugs. Epidermal growth factor receptor (EGFR), as one of the most critical anti-cancer targets belonging to the receptor tyrosine kinase family, represents a quintessential example. It was revealed that osimertinib, an ATP-competitive covalent EGFR inhibitor, remarkably enhanced the affinity of a recently developed allosteric inhibitor JBJ-04-125-02 for EGFRL858R/T790M. Here, we utilized extensive large-scale molecular dynamics simulations and the reversed allosteric communication to untangle the detailed molecular underpinning, in which occupation of osimertinib at the orthosteric site altered the overall conformational ensemble of EGFR mutant and reshaped the allosteric site via long-distance signaling. A unique intermediate state resembling the active conformation was identified, which was further stabilized by osimertinib loading. Based on the allosteric communication pathway, we predicted a novel allosteric site positioned around K867, E868, H893, and K960 within the intermediate state. Its correlation with the orthosteric site was validated by both structural and energetic analysis, and its low sequence conservation indicated the potential for selective targeting across the human kinome. Together, these findings not only provided a mechanistic basis for future clinical application of the dual-targeting therapeutics, but also explored an innovative perception of allosteric inhibition of tyrosine kinase signaling.
18 February 2026 in Frontiers in Cell and Developmental Biology
Cancer immunotherapy has revolutionized oncology but faces significant challenges including low response rates and lack of effective preclinical models. This review elucidates how patient-derived organoids (PDOs) are emerging as a transformative platform to address these hurdles. We detail sophisticated immuno-PDO (iPDO) models, categorized into reconstituted systems (co-culturing PDOs with exogenous immune cells) and native systems (preserving endogenous tumor microenvironment via Air-Liquid Interface or Patient-Derived Organotypic Tumor Spheroids). A problem-solution framework demonstrates how iPDOs: (1) deconvolute the immunosuppressive TME; (2) function as “living biomarkers” for predicting clinical responses; (3) unravel resistance mechanisms via multi-omics; and (4) empower high-throughput screening for personalized combination therapies. Integration with bioengineering, multi-omics, and AI heralds a new era in precision immuno-oncology, holding immense promise for deciphering resistance and improving clinical outcomes.
Adjuvant chemotherapy has shown favorable outcomes for pancreatic cancer. However, the role of adding radiotherapy to chemotherapy remained conflicting and lacked robust evidence to show improved survival compared with chemotherapy alone. Previous meta-analyses based on retrospective studies and database demonstrated that patients with lymph nodal metastases, positive microscopic margins or positive margins, or lymphovascular invasion may obtain survival benefits from adjuvant chemoradiotherapy. This multicenter, randomized, open-label, phase III trial aim to compare the efficacy of adjuvant chemoradiotherapy and chemotherapy for pancreatic cancer harboring pathological features predictive of a high risk of recurrence. Seven hundred and seventy patients will be recruited and randomized in a 1:1 ratio into the adjuvant chemoradiotherapy and chemotherapy group. Patients will receive gemcitabine and capecitabine in adjuvant chemotherapy group. In the adjuvant chemoradiotherapy group, patients will first receive the same regimen as that of the adjuvant chemotherapy group and then concurrent chemoradiotherapy (the prescription dose of 50-54 Gy in 25-27 fractions and capecitabine). ADJUPANC aims to investigate whether adjuvant chemoradiotherapy contributes to favorable outcomes for patients with pancreatic cancer harboring lymph nodal metastases, positive microscopic margins or positive margins, or lymphovascular invasion compared with adjuvant chemotherapy. This may provide evidence for individualized treatment for pancreatic cancer.Clinical trial registration: www.clinicaltrials.gov identifier is NCT06427447.